These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

133 related articles for article (PubMed ID: 24258070)

  • 21. Immune complexes from rheumatoid arthritis synovial fluid induce FcgammaRIIa dependent and rheumatoid factor correlated production of tumour necrosis factor-alpha by peripheral blood mononuclear cells.
    Mathsson L; Lampa J; Mullazehi M; Rönnelid J
    Arthritis Res Ther; 2006; 8(3):R64. PubMed ID: 16569263
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Leflunomide combined with conventional disease-modifying antirheumatic drugs or biologics in patients with rheumatoid arthritis.
    Combe B
    Joint Bone Spine; 2006 Dec; 73(6):587-90. PubMed ID: 17071123
    [No Abstract]   [Full Text] [Related]  

  • 23. RNA released from necrotic synovial fluid cells activates rheumatoid arthritis synovial fibroblasts via Toll-like receptor 3.
    Brentano F; Schorr O; Gay RE; Gay S; Kyburz D
    Arthritis Rheum; 2005 Sep; 52(9):2656-65. PubMed ID: 16142732
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Rheumatoid arthritis: Missed opportunities in the 2015 ACR guideline for RA treatment.
    van Vollenhoven R
    Nat Rev Rheumatol; 2016 Mar; 12(3):135-6. PubMed ID: 26763731
    [No Abstract]   [Full Text] [Related]  

  • 25. Adherence to biologic DMARD therapies in rheumatoid arthritis.
    Koncz T; Pentek M; Brodszky V; Ersek K; Orlewska E; Gulacsi L
    Expert Opin Biol Ther; 2010 Sep; 10(9):1367-78. PubMed ID: 20681888
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Synovial fluid IL-6 concentrations associated with positive response to tocilizumab in an RA patient with failed response to anti-TNF and rituximab.
    Wright HL; Mewar D; Bucknall RC; Edwards SW; Moots RJ
    Rheumatology (Oxford); 2015 Apr; 54(4):743-4. PubMed ID: 25667432
    [No Abstract]   [Full Text] [Related]  

  • 27. First-time prescriptions of biological disease-modifying antirheumatic drugs in rheumatoid arthritis, psoriatic arthritis and axial spondyloarthritis 2002-2011: data from the NOR-DMARD register.
    Lie E; Fagerli KM; Mikkelsen K; Rødevand E; Lexberg A; Kalstad S; Uhlig T; Kvien TK
    Ann Rheum Dis; 2014 Oct; 73(10):1905-6. PubMed ID: 24989896
    [No Abstract]   [Full Text] [Related]  

  • 28. Use of biologic agents in rheumatoid arthritis: introduction.
    Silman AJ
    Rheumatology (Oxford); 2011 Sep; 50 Suppl 4():iv3-4. PubMed ID: 21859703
    [No Abstract]   [Full Text] [Related]  

  • 29. Novel insights in the regulation of CCL18 secretion by monocytes and dendritic cells via cytokines, toll-like receptors and rheumatoid synovial fluid.
    van Lieshout AW; van der Voort R; le Blanc LM; Roelofs MF; Schreurs BW; van Riel PL; Adema GJ; Radstake TR
    BMC Immunol; 2006 Sep; 7():23. PubMed ID: 16984635
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Hypoxia and hypoxia-inducible factor-1α provoke toll-like receptor signalling-induced inflammation in rheumatoid arthritis.
    Hu F; Mu R; Zhu J; Shi L; Li Y; Liu X; Shao W; Li G; Li M; Su Y; Cohen PL; Qiu X; Li Z
    Ann Rheum Dis; 2014 May; 73(5):928-36. PubMed ID: 23644550
    [TBL] [Abstract][Full Text] [Related]  

  • 31. [Rheumatoid arthritis: progress in diagnosis and treatment. Topics: IV. Treatment 2. Antirheumatic agents, 2) biological agents].
    Amano K
    Nihon Naika Gakkai Zasshi; 2012 Oct; 101(10):2880-5. PubMed ID: 23214097
    [No Abstract]   [Full Text] [Related]  

  • 32. Updated recommendations for the treatment of rheumatoid arthritis: another step on a long road.
    Daikh DI; St Clair EW
    Arthritis Care Res (Hoboken); 2012 May; 64(5):648-51. PubMed ID: 22473919
    [No Abstract]   [Full Text] [Related]  

  • 33. Rheumatoid arthritis: are current research-based guidelines clinically relevant?
    Kafaja S; Furst DE
    J Rheumatol; 2014 Aug; 41(8):1569-70. PubMed ID: 25086136
    [No Abstract]   [Full Text] [Related]  

  • 34. The role of toll-like receptors in rheumatoid arthritis.
    Huang QQ; Pope RM
    Curr Rheumatol Rep; 2009 Oct; 11(5):357-64. PubMed ID: 19772831
    [TBL] [Abstract][Full Text] [Related]  

  • 35. The 2008 American College of Rheumatology recommendations for the use of nonbiologic and biologic disease-modifying antirheumatic drugs in rheumatoid arthritis: where the rubber meets the road.
    Bathon JM; Cohen SB
    Arthritis Rheum; 2008 Jun; 59(6):757-9. PubMed ID: 18512712
    [No Abstract]   [Full Text] [Related]  

  • 36. IL-6 targeting compared to TNF targeting in rheumatoid arthritis: studies of olokizumab, sarilumab and sirukumab.
    Tanaka Y; Martin Mola E
    Ann Rheum Dis; 2014 Sep; 73(9):1595-7. PubMed ID: 24833786
    [No Abstract]   [Full Text] [Related]  

  • 37. Rheumatoid arthritis.
    Lorenzo M
    Foot Ankle Clin; 2007 Sep; 12(3):525-37, vii. PubMed ID: 17765843
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Soluble CD93 induces differentiation of monocytes and enhances TLR responses.
    Jeon JW; Jung JG; Shin EC; Choi HI; Kim HY; Cho ML; Kim SW; Jang YS; Sohn MH; Moon JH; Cho YH; Hoe KL; Seo YS; Park YW
    J Immunol; 2010 Oct; 185(8):4921-7. PubMed ID: 20861352
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Advances. A new era in treating arthritis.
    Emery P
    Health Serv J; 2009 Dec; 119(6186):suppl 1-2. PubMed ID: 20128083
    [No Abstract]   [Full Text] [Related]  

  • 40. Oral glucocorticoids should be included in any recommendation for the use of nonbiologic and biologic disease-modifying antirheumatic drugs in the treatment of rheumatoid arthritis: comment on the article by Singh et al.
    Conn DL
    Arthritis Care Res (Hoboken); 2012 Oct; 64(10):1622-3; author reply 1623-4. PubMed ID: 23024030
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.